Refractory Blastic Plasmacytoid Dendritic Cell Neoplasm: Clinical Trials

5 trials for Refractory Blastic Plasmacytoid Dendritic Cell Neoplasm, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

2 recruiting, 1 completed, 1 terminated, 1 withdrawn. 3 Phase 1, 2 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 13Recruiting 2, Completed 1
Phase 22Terminated 1, Withdrawn 1

Follow Refractory Blastic Plasmacytoid Dendritic Cell Neoplasm: new trials by email Literature Review of Refractory Blastic Plasmacytoid Dendritic Cell Neoplasm trials Research Report on Refractory Blastic Plasmacytoid Dendritic Cell Neoplasm

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Q702 for the Treatment of Patients With Hematologic Malignancies
Axl/Mer/CSF1R Inhibitor Q702, Biospecimen Collection, Bone Marrow Aspiration - Hematopoietic and Lymphatic System Neoplasm, Histiocytic Sarcoma
Phase 1RecruitingMayo Clinic462025-08-272025-10-10
Flotetuzumab for the Treatment of Relapsed or Refractory Advanced CD123-Positive Hematological Malignancies
Acetaminophen, Dexamethasone, Diphenhydramine - Recurrent Acute Leukemia, Recurrent B Acute Lymphoblastic Leukemia
Phase 1CompletedCity of Hope Medical Center132020-11-182026-01-28
Flotetuzumab in Treating Patients With Recurrent or Refractory CD123 Positive Blood Cancer
Anti-CD123/CD3 Monoclonal Antibody MGD006 - Acute Biphenotypic Leukemia, Acute Leukemia
Phase 2WithdrawnCity of Hope Medical Center2020-10-202020-12-17
HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant
CD8+ and CD4+ Donor Memory T-cells-expressing HA1-Specific TCR, Bone Marrow Aspiration, Biospecimen Collection - Juvenile Myelomonocytic Leukemia, Recurrent Acute Biphenotypic Leukemia
Phase 1RecruitingFred Hutchinson Cancer Center242018-02-232026-05-18
Venetoclax and Decitabine in Treating Participants With Relapsed/Refractory Acute Myeloid Leukemia or Relapsed High-Risk Myelodysplastic Syndrome
Decitabine, Laboratory Biomarker Analysis, Venetoclax - Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome
Phase 2TerminatedM.D. Anderson Cancer Center2352018-01-182026-03-10

Narrower conditions

Blastic Plasmacytoid Dendritic Cell Neoplasm (5)  ·  Leukemia, Biphenotypic, Acute (3)  ·  Leukemia, Myelogenous, Chronic, BCR-ABL Positive (3)  ·  Leukemia, Myelomonocytic, Chronic (3)  ·  Myelodysplastic Syndromes (3)  ·  Hematologic Neoplasms (2)  ·  Hodgkin Disease (2)  ·  Leukemia, Hairy Cell (2)  ·  Leukemia, Myeloid, Acute (2)  ·  Mastocytosis, Systemic (2)  ·  Precursor Cell Lymphoblastic Leukemia-Lymphoma (2)  ·  Blast Crisis (1)  ·  Burkitt Lymphoma (1)  ·  Dendritic Cell Sarcoma, Interdigitating (1)  ·  Erdheim-Chester Disease (1)

Broader conditions

Bone Marrow Diseases (5)  ·  Chronic Disease (5)  ·  Disease Attributes (5)  ·  Hematologic Diseases (5)  ·  Hemic and Lymphatic Diseases (5)  ·  Histiocytic Disorders, Malignant (5)  ·  Immune System Diseases (5)  ·  Immunoproliferative Disorders (5)  ·  Leukemia, Lymphoid (5)  ·  Leukemia, Myeloid (5)  ·  Lymphatic Diseases (5)  ·  Lymphoma (5)  ·  Lymphoproliferative Disorders (5)  ·  Neoplasms (5)  ·  Neoplasms by Histologic Type (5)

Interventions

Acetaminophen (1)  ·  Biopsy (1)  ·  Calcium Dobesilate (1)  ·  Decitabine (1)  ·  Dexamethasone (1)  ·  Diphenhydramine (1)  ·  Ibuprofen (1)  ·  Injections (1)  ·  Magnetic Resonance Spectroscopy (1)  ·  Ranitidine (1)  ·  Specimen Handling (1)  ·  auricularum (1)  ·  dexamethasone 21-phosphate (1)  ·  dexamethasone acetate (1)  ·  venetoclax (1)

Sponsors

City of Hope Medical Center (2)  ·  Fred Hutchinson Cancer Center (1)  ·  M.D. Anderson Cancer Center (1)  ·  Mayo Clinic (1)

Countries

United States (4)

Top investigators

Abhishek Maiti, MBBS (1)  ·  Elizabeth Krakow (1)  ·  Ibrahim Aldoss, MD (1)  ·  Ibrahim T Aldoss (1)  ·  Jithma P. Abeykoon, MD (1)

Results publications

PMID 32896301, PMID 33027528, PMID 33580980, PMID 33792630, PMID 34255353, PMID 34474640, PMID 35622074, PMID 38683966

NIH funding

P30CA033572 (1)